参考文献/References:
［1］SIEGEL R L, MILLER K D, STATISTICS J C, et al. Cancer statistics，2015.CA ［J］. A Cancer J Clinicians, 2015, 65(1): 5-29.
［2］NELSON H D, PAPPAS M, CANTOR A, et al. Risk assessment,genetic counseling,and genetic testing for BRCA-Related cancer in women:updated evidence report and systematic review for the US preventive services task force ［J］. JAMA : the Journal of the American Medical Association, 2019, 322(7): 666-685.
［3］REITSMA W, DE BOCK G H, OOSTERWIJK J C, et al. Support of the `fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens ［J］. European Journal of Cancer, 2013, 49(1): 132-141.
［4］SHERMAN M E, PIEDMONTE M, MAI P L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from gynecologic oncology group trial GOG-0199 ［J］. Journal of Clinical Oncology, 2014, 32(29): 3275-3283.
［5］HARTMANN L C, LINDOR N M. The role of Risk-Reducing surgery in hereditary breast and ovarian cancer ［J］. New England Journal of Medicine, 2016, 374(5): 454-468.
［6］BRISTOW R E, TOMACRUZ R S, ARMSTRONG D K, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the Platinum era: a meta-analysis ［J］. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2002, 20(5): 1248-1259.
［7］VERGOTE I, TROPE C G, AMANT F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer ［J］. The New England Journal of Medicine, 2010, 363(10): 943-953.
［8］RAUH-HAIN J A, RODRIGUEZ N, GROWDON W B, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer ［J］. Annals of Surgical Oncology, 2012, 19(3): 959-965.
［9］KEHOE S, HOOK J, NANKIVELL M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial ［J］. Lancet, 2015, 386(9990): 249-257.
［10］ONDA T, SATOH T, SAITO T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602 ［J］. European Journal of Cancer, 2016, 64(9): 22-31.
［11］RAUH-HAIN J A, MELAMED A, WRIGHT A A, et al. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer analysis of the National cancer database ［J］. JAMA ONCOLOGY, 2017, 3(1): 76-82.
［12］HARTER P, SEHOULI J, LORUSSO D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms ［J］. New England Journal of Medicine, 2019, 380(9): 822-832.
［13］BRISTOW R E, PURI I, CHI D-s. Cytoreductive surgery for recurrent ovarian cancer:a meta-analysis ［J］. Gynecologic Oncology, 2009, 112(1): 265-274.
［14］Harter P,Sehouli J,Meier W,et al. Randomized controlled phase III study to evaluat the impact of secondary cytorecuctive surgery in recurrent ovarian cancer- AGO DESKTOP III/ENGOT ov20 ［J］. Geburtshilfe Frauenheilkd，2018，78（10）：94.
［15］RL1 C. Brady MF,herzog TJ.bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent,platinum-sensitive ovarian cancer(NRG oncology/gynecologic oncology group study GOG-0213):amulticentre,open-label,randomised,phase 3 trial ［J］. Lancet Oncology, 2017, 18(6): 779-791.
［16］REICH H, MCGLYNN F, WILKIE W. Laparoscopic management of stage I ovarian cancer.A case report ［J］. Journal of Reproductive Medicine, 1990, 35(6): 601-605.
［17］JUNG U S, LEE J H, KYUNG M S, et al. Feasibility and efficacy of laparoscopic management of ovarian cancer ［J］. The Journal of Obstetrics and Gynaecology Research, 2009, 35(1): 113-118.
［18］COLOMER A T, JIMENEZ A M, BARCELO M. Laparoscopic treatment and staging of early ovarian cancer ［J］. Journal of Minimally Invasive Gynecology, 2008, 15(4): 414-419.
［19］FADER A N, ESCOBAR P F. Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: Technique and initial report ［J］. Gynecologic Oncology, 2009, 114(2): 157-161.
［20］FANNING J, YACOUB E, HOJAT R. Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: Success, morbidity and survival ［J］. Gynecologic Oncology, 2011, 123(1): 47-49.
［21］MELAMED A, NITECKI R, BORUTA I D, et al. Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy ［J］. Obstetrics and Gynecology, 2017, 129(5): 861-869.
［22］FAGOTTI A, FANFANI F, LUDOVISI M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer:a pilot study ［J］. Gynecologic Oncology, 2005, 96(3): 729-735.
［23］PETRILLO M, VIZZIELLI G, FANFANI F, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept ［J］. Gynecologic Oncology, 2015, 139(1): 5-9.
［24］RUTTEN M J, VAN MEURS H S, VAN DE VRIE R, et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial ［J］. Journal of Clinical Oncology, 2017, 35(6): 613-621.
［25］BANDERA C A, MAGRINA J F. Robotic surgery in gynecclogic oncology ［J］. Current Opinion in Obstetrics & Gynecology, 2009, 21(1): 25-30.
［26］YOO J G, KIM W J, LEE K H. Single-Site Robot-Assisted laparoscopic staging surgery for presumed clinically Early-Stage ovarian cancer ［J］. Journal of Minimally Invasive Gynecology, 2018, 25(3): 380-381.
相似文献/References:
[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(10):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(10):15.
[4]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(10):59.
[5]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(10):72.
[6]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后
患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with
lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):72.
[7]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析（附38例报道）[J].中国计划生育和妇产科,2018,(3):37.
SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian
malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):37.
[8]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58.
YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):58.
[9]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):62.
[10]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.